Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.21) by 4.76 percent. This is a 24.14 percent increase over losses of $(0.29) per share from the same period last year. The company reported $172.00 thousand in sales this quarter.